TITLE

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol

AUTHOR(S)
Rubio-Valera, Maria; Serrano-Blanco, Antoni; Travé, Pere; Teresa Peñarrubia-María, M.; Ruiz, Mar; Pujol, Marian March
PUB. DATE
January 2009
SOURCE
BMC Public Health;2009, Vol. 9, p284
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and cost-effectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196
ACCESSION #
44171666

 

Related Articles

  • Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Capoccia, Kam L.; Boudreau, Denise M.; Blough, David K.; Ellsworth, Allan J.; Clark, Dave R.; Stevens, Nancy G.; Katon, Wayne J.; Sullivan, Sean D. // American Journal of Health-System Pharmacy;2/15/2004, Vol. 61 Issue 4, p364 

    The impact of pharmacist interventions on the care and outcomes of patients with depression in a primary care setting was evaluated. Patients diagnosed with a new episode of depression and started on antidepressant medications were randomized to enhanced care (EC) or usual care (UC) for one...

  • Placebo-Controlled Trial of Lithium Augmentation of Fluoxetine and Lofepramine. Katona, Cornelius L. E.; Abou-Saleh, Mohammed T.; Harrison, Deborah A.; Nairac, Bertrand A.; Edwards, Denzil R. L.; Lock, Toni; Burns, Robert A.; Robertson, Mary M. // British Journal of Psychiatry;Jan95, Vol. 166, p80 

    Background. This study was designed to establish whether (as suggested in a number of open and relatively small controlled trials) lithium augmentation is more effective than continued antidepressant alone, where response to a standard course of antidepressant treatment has been absent or...

  • Should We Treat Depression with drugs or psychological interventions? A Reply to Ioannidis. Davis, John M.; Giakas, William J.; Jie Qu; Prasad, Pavan; Leucht, Stefan // Philosophy, Ethics & Humanities in Medicine;2011, Vol. 6 Issue 1, p8 

    We reply to the Ioannidis's paper "Effectiveness of antidepressants; an evidence based myth constructed from a thousand controlled trials." We disagree that antidepressants have no greater efficacy than placebo. We present the efficacy from hundreds of trials in terms of the percentage of...

  • Depression Update.  // PharmaWatch: CNS;Mar2006, Vol. 5 Issue 3, p9 

    The article reports that Clinical Data Inc. is starting patient enrollment for a phase III clinical trial of vilazodone, a compound for treating depression. The successful outcome of the testing would serve as one of the trials required for a new drug application in the U.S. Clinical Data plans...

  • The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes. Bech, P.; Gefke, M.; Lunde, M.; Lauritzen, L.; Martiny, K. // Depression Research & Treatment;2011, p1 

    Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D6. Methods....

  • The effect of adalimumab on reducing depression symptoms in patients with moderate-to-severe psoriasis: a randomized clinical trial.  // Advances in Psoriasis & Inflammatory Skin Diseases;2010, Vol. 2 Issue 1, p25 

    The article presents the randomized clinical trial on the effect of adalimumab on the reduction of depression symptoms in patients suffering moderate-to-severe psoriasis. The study shows the association of psoriasis with increased rates of emotional and psychological disorders and impaired...

  • A Home-Based Intervention to Reduce Depressive Symptoms and Improve Quality of Life in Older African Americans. Gitlin, Laura N.; Fields Harris, Lynn; McCoy, Megan C.; Chernett, Nancy L.; Pizzi, Laura T.; Jutkowitz, Eric; Hess, Edward; Hauck, Walter W. // Annals of Internal Medicine;8/20/2013, Vol. 159 Issue 4, p243 

    Background: Effective care models for treating older African Americans with depressive symptoms are needed. Objective: To determine whether a home-based intervention alleviates depressive symptoms and improves quality of life in older African Americans. Design: Parallel, randomized trial...

  • Escitalopram cost effective vs venlafaxine XR in MDD.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p7 

    Looks at the effectiveness of escitalopram in the treatment of major depressive disorder. Results of an economic evaluation and clinical trials among depressive disorder patients; Use of Quality of Life Depression Scale in the assessment of the patients; Lower costs associated with escitalopram...

  • Bial reports positive results from Phase III studies of seizure drug.  // PharmaWatch: CNS;Nov2008, Vol. 7 Issue 11, p6 

    The article presents the results from the Phase III studies of Bial SA, a Portuguese pharmaceutical company, regarding the positive effect of Zebinix, an antiepileptic agent. The studies found that Zebinix, in combination with other anti-epileptic agents, has significantly reduced the frequency...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics